Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Inventory: 2022-2025

Historic Inventory for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $23.8 million.

  • Axsome Therapeutics' Inventory rose 66.66% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 66.66%. This contributed to the annual value of $15.7 million for FY2024, which is 3.94% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Inventory stood at $23.8 million, which was up 28.92% from $18.4 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Inventory peaked at $23.8 million during Q3 2025, and registered a low of $4.3 million during Q4 2022.
  • For the 3-year period, Axsome Therapeutics' Inventory averaged around $14.7 million, with its median value being $15.2 million (2024).
  • Data for Axsome Therapeutics' Inventory shows a peak YoY increase of 250.35% (in 2023) and a maximum YoY decrease of 28.62% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Inventory stood at $4.3 million in 2022, then spiked by 250.35% to $15.1 million in 2023, then grew by 3.94% to $15.7 million in 2024, then spiked by 66.66% to $23.8 million in 2025.
  • Its Inventory was $23.8 million in Q3 2025, compared to $18.4 million in Q2 2025 and $16.3 million in Q1 2025.